Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-market study evaluating clinical benefits of Arikayce

Trial Profile

A post-market study evaluating clinical benefits of Arikayce

Status: Planning
Phase of Trial: Phase IV

Latest Information Update: 07 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Mycobacterium avium complex infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 May 2019 According to an Insmed media release, the company expects to complete the design and protocol of this confirmatory clinical study during the first half of 2019 required for the full U.S. approval of ARIKAYCE by the FDA.
    • 08 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top